MEK Inhibitors Market: How Is Neurofibromatosis Type 1 Approval...

added blog Health

2026-07-10 10:32:21 -

MEK Inhibitors Market: How Is Neurofibromatosis Type 1 Approval Creating a New Rare-Disease Revenue Stream?

MEK inhibitors targeting neurofibromatosis type 1-associated plexiform neurofibromas — the oral allosteric MEK1/2 inhibitors selumetinib (Koselugo, AstraZeneca) and mirdametinib (Gomekli, SpringWorks Therapeutics) approved for pediatric and adult NF1 patients with symptomatic, inoperable tumors — represent the fastest-growing indication segment in the MEK inhibitor market, with the...

0 Comments 0 Shares 15 Views 0 Reviews